ATE526953T1 - Verwendung von 5-ht7-rezeptor-agonisten zur behandlung von schmerzen - Google Patents

Verwendung von 5-ht7-rezeptor-agonisten zur behandlung von schmerzen

Info

Publication number
ATE526953T1
ATE526953T1 AT07785870T AT07785870T ATE526953T1 AT E526953 T1 ATE526953 T1 AT E526953T1 AT 07785870 T AT07785870 T AT 07785870T AT 07785870 T AT07785870 T AT 07785870T AT E526953 T1 ATE526953 T1 AT E526953T1
Authority
AT
Austria
Prior art keywords
receptor agonists
pain
treat pain
symptoms
neuropathic pain
Prior art date
Application number
AT07785870T
Other languages
English (en)
Inventor
Hernandez Jose Vela
Antonio Torrens-Jover
Helmut Buschmann
Luz Romero-Alonso
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Application granted granted Critical
Publication of ATE526953T1 publication Critical patent/ATE526953T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07785870T 2006-06-29 2007-06-29 Verwendung von 5-ht7-rezeptor-agonisten zur behandlung von schmerzen ATE526953T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06013496A EP1875899A1 (de) 2006-06-29 2006-06-29 Verwendugng von Agonisten des 5HT7 Rezeptors in der Behandlung von Schmerzen
PCT/EP2007/005776 WO2008000495A1 (de) 2006-06-29 2007-06-29 Use of 5-ht7 receptor agonists for the treatment of pain

Publications (1)

Publication Number Publication Date
ATE526953T1 true ATE526953T1 (de) 2011-10-15

Family

ID=37308928

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07785870T ATE526953T1 (de) 2006-06-29 2007-06-29 Verwendung von 5-ht7-rezeptor-agonisten zur behandlung von schmerzen

Country Status (5)

Country Link
US (1) US20090326014A1 (de)
EP (2) EP1875899A1 (de)
AT (1) ATE526953T1 (de)
ES (1) ES2374739T3 (de)
WO (1) WO2008000495A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9220054B2 (en) 2009-12-22 2015-12-22 Intel Corporation Enhanced service discovery mechanism in wireless communication system
EP2676954A1 (de) 2012-06-19 2013-12-25 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituierte Phenylderivate als Vasodilatoren
WO2014164756A1 (en) 2013-03-11 2014-10-09 Temple University Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
WO2016040554A1 (en) 2014-09-10 2016-03-17 Temple University-Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
ES3050660T3 (en) 2016-11-15 2025-12-22 Univ Temple 3-(2-(4-phenylpiperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one derivatives and related compounds as 5-hydroxytryptamine receptor 7 (5-ht7) modulators for treating e.g. inflammatory bowel disease, circadian rhythm disorder or depression
US11220505B2 (en) 2017-03-21 2022-01-11 Temple University-Of The Commonwealth System Of Higher Education 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents
MA52567A (fr) 2018-05-11 2021-03-17 Praeventix Llc Nouveaux lactames fonctionnalisés en tant que modulateurs du récepteur de 5-hydroxytryptamine 7 et leur procédé d'utilisation
EP3870292A4 (de) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York Kombination von serotonin-spezifischem wiederaufnahmeinhibitor und serotonin-1a-rezeptor-partialagonist zur verminderung von l-dopa-induzierter dyskinesie
WO2021097117A2 (en) 2019-11-13 2021-05-20 Temple University-Of The Commonwealth System Of Higher Education Novel functionalized lactones as modulators of the 5-hydroxytryptamine receptor 7 and their method of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19542281C2 (de) * 1995-11-14 1997-12-04 Boehringer Ingelheim Kg Verwendung von Epinastin für die Behandlung der Migräne
EP1222185A1 (de) * 1999-10-18 2002-07-17 Smithkline Beecham Plc Tetrahydrobenzindolon-derivate, deren herstellung und deren verwendung als 5-ht7 rezeptor antagonisten
ATE315023T1 (de) * 2000-10-30 2006-02-15 Warner Lambert Co Aminoalkylpyrrolidine als serotoninrezeptorliganden sowie diese enthaltende zusammensetzungen, pharmazeutische verwendungen und methoden zu deren synthese
EP1676840A1 (de) * 2004-12-28 2006-07-05 Laboratorios Del Dr. Esteve, S.A. 5-HT7-Rezeptorantagonisten
EP1634081A2 (de) * 2003-05-28 2006-03-15 Bayer HealthCare AG Diagnostika und therapeutika für krankheiten, die mit dem 5-hydroxytryptamin (serotonin) receptor 7 (5-ht7) assoziiert sind
GB0316128D0 (en) * 2003-07-10 2003-08-13 Univ Aston Novel sulfonamide compounds
ES2257168B1 (es) * 2004-08-18 2007-06-01 Laboratorios Del Dr Esteve, S.A. Ligandos del receptor 5-ht7.

Also Published As

Publication number Publication date
EP2049090B1 (de) 2011-10-05
EP2049090A1 (de) 2009-04-22
US20090326014A1 (en) 2009-12-31
EP1875899A1 (de) 2008-01-09
WO2008000495A1 (de) 2008-01-03
ES2374739T3 (es) 2012-02-21

Similar Documents

Publication Publication Date Title
ATE526953T1 (de) Verwendung von 5-ht7-rezeptor-agonisten zur behandlung von schmerzen
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
BRPI0514017A (pt) indazóis úteis no tratamento de doenças cardiovasculares
ZA200703002B (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
EA200900021A1 (ru) Пептидные соединения для лечения рефрактерного эпилептического статуса
EA200801897A1 (ru) Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений
GT200800166A (es) Derivados de octahidro-pirrol (3,4-b) pirrol
EA201690265A3 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
MY152282A (en) Compositions and methods for use antibodies against sclerostin
EP1756106A4 (de) Cyclohexylalaninderivate als dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes
EA201100523A1 (ru) Соединения сульфонила, которые селективно модулируют рецептор св2
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
MY148851A (en) Dihydropyridine derivatives as useful as protein kinase inhibitors
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
EA201171063A1 (ru) Фармацевтические составы олмесартана
EA201200019A1 (ru) Соединения, которые селективно модулируют рецептор св2
EA200971141A1 (ru) Соединения, активирующие теломеразу, и способы их применения
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
MX2009003981A (es) Agentes moduladores del receptor de calcio.
MX356813B (es) Derivados de hidantoina utiles como inhibidores de kv3.
ATE505191T1 (de) Ectoin zur behandlung von vascular leaks
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties